Abstract
Purpose
A study comparing intracorporeal injection of prostaglandin E1 (one-drug solution) and papaverine plus prostaglandin E1 (2-drug solution) for treatment of impotence.
Materials and methods
A total of 100 impotent patients had intracorporeal injections of the one-drug and 2-drug solution alternatively in 3 sessions. The quality and duration of erections were assessed.
Results
Seventy-five per cent of the patients developed full erection with the 2-drug solution compared to 50% with the one-drug solution. The average duration of erections was 60 minutes and 45 minutes, respectively. The complication rate was higher for the 2-drug solution.
Conclusion
Papaverine plus prostaglandin E1 is superior to prostaglandin E1 alone for treatment of impotence, but has a higher rate of complications. Intracavernous injection of vasoactive drugs is a very effective and important way for treatment of impotence. Papaverine plus prostaglandin E1 had been used for treatment of impotence alone or combined. A blind study was done to compare efficiency and complication rates of intracavernous injection of papaverine plus prostaglandin E1 (2-drug solution) with prostaglandin E1 alone.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Althof, S. E., Turner, L. A., Levine, S. B., Risen, C., Kursh, E., Bodner, D., Resnick, M.: Why do so many people drop out from auto-injection therapy for impotence?J. Sex. Marital. Ther., 15, 121 (1989).
Bennett, A. H., Carpenter, A. J., Barada, J. H.: An improved vasoactive drug combination for a pharmacological erection program.J. Urol., 146, 1564 (1991).
Brindley, G. S.: Cavernosal alpha-blockade: A new technique for investigating and treating erectile impotence.Br. J. Psychiatr., 43, 332 (1983).
Floth, A., Schramek, P.: Intracavernous injection of prostaglandin E1 in combination with papaverine: Enhanced effectiveness in comparison with papaverine plus phentolamine and prostaglandin E1 alone.J. Urol., 145, 56 (1991).
Hedlund, H., Anderson, K.-E.: Contraction and relaxation induced by some protanoids in isolated human penile erectile tissue and cavernous artery.J. Urol., 134, 245 (1985).
Lakin, M. M., Mondague, D. K., Vander Brug Medendorp, S., Tesar, L., Schover, L. R.: Intracavernous injection therapy, analysis of results and complications.J. Urol., 143, 1138 (1990).
Levine, S. B., Althof, S. E., Turner, L. A., Risen, C. B., Bodner, D. R., Kursh, E. D., Resnick, M. I.: Side effects of self-administration of intracavernous papaverine and phentolamine for the treatment of impotence.J. Urol., 141, 54 (1989).
Sidi, A. A., Chen, K. K.: Clinical experience with vasoactive intracavernous pharmacotherapy for the treatment of impotence.World J. Urol., 5, 156 (1987).
Shenfeld, O., Hanani, J., Shalhaw, A., Vardi, Y., Goldwasser, B.: Papaverine-phentolamine and prostaglandin E1 versus papaverine-phentolamine alone for intracorporeal injection therapy: A clinical double blind study.J. Urol., 154, 1017 (1995).
Von-Heyden, B., Donatucci, C. F., Kaula, N., Lue, T. F.: Intracavernous pharmacotherapy for impotence: Selection of appropriate agent and dose.J. Urol., 149, 1288 (1993).
Zentgraf, M., Ludiving, G., Ziegler, M.: How safe is the treatment of impotence with intracavernous autoinjection?.Eur. Urol., 16, 165 (1989).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Zaher, T.F. Papaverine plus prostaglandin E1 versus prostaglandin E1 alone for intracorporeal injection therapy. International Urology and Nephrology 30, 193–196 (1998). https://doi.org/10.1007/BF02550576
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02550576